下痢治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Diarrhea - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0677
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年1月14日
◆ページ数:153
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Diarrhea – Pipeline Review, H1 2020
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Diarrhea – Pipeline Review, H1 2020, provides an overview of the Diarrhea (Gastrointestinal) pipeline landscape.

Diarrhea is a contagious gastrointestinal infection occurring mostly due to unhygienic conditions. Diarrhea may be related to a viral or bacterial infection and is sometimes the result of food poisoning. Symptoms include nausea, abdominal pain, cramping, bloating, dehydration, fever, bloody stools, frequent urge to evacuate the bowels and incontinence. Treatment includes medication and healthy lifestyle.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Diarrhea – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Diarrhea (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diarrhea (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Diarrhea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 13, 2, 15 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 3 and 5 molecules, respectively.

Diarrhea (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Diarrhea (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Diarrhea (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diarrhea (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diarrhea (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diarrhea (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diarrhea (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diarrhea (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Introduction
Diarrhea – Overview
Diarrhea – Therapeutics Development
Diarrhea – Therapeutics Assessment
Diarrhea – Companies Involved in Therapeutics Development
Diarrhea – Drug Profiles
Diarrhea – Dormant Projects
Diarrhea – Discontinued Products
Diarrhea – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Diarrhea, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Diarrhea - Pipeline by Akthelia Pharmaceuticals Ltd, H1 2020
Diarrhea - Pipeline by Albireo Pharma Inc, H1 2020
Diarrhea - Pipeline by Allergan Plc, H1 2020
Diarrhea - Pipeline by Artugen Therapeutics Ltd, H1 2020
Diarrhea - Pipeline by AzurRx BioPharma Inc, H1 2020
Diarrhea - Pipeline by Boston Pharmaceuticals Inc, H1 2020
Diarrhea - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2020
Diarrhea - Pipeline by Codagenix Inc, H1 2020
Diarrhea - Pipeline by Cosmo Pharmaceuticals NV, H1 2020
Diarrhea - Pipeline by DiscoveryBiomed Inc, H1 2020
Diarrhea - Pipeline by Glycosyn LLC, H1 2020
Diarrhea - Pipeline by Immuron Ltd, H1 2020
Diarrhea - Pipeline by Kaleido Biosciences Inc, H1 2020
Diarrhea - Pipeline by Kuhnil Pharmaceutical Co Ltd, H1 2020
Diarrhea - Pipeline by Miyarisan Pharmaceutical Company Ltd, H1 2020
Diarrhea - Pipeline by MSD Wellcome Trust Hilleman Laboratories Pvt Ltd, H1 2020
Diarrhea - Pipeline by MyBiotics Pharma Ltd, H1 2020
Diarrhea - Pipeline by Napo Pharmaceuticals Inc, H1 2020
Diarrhea - Pipeline by Nippon Shinyaku Co Ltd, H1 2020
Diarrhea - Pipeline by Novartis AG, H1 2020
Diarrhea - Pipeline by Orphomed Inc, H1 2020
Diarrhea - Pipeline by Pharmascience Inc, H1 2020
Diarrhea - Pipeline by Prokarium Ltd, H1 2020
Diarrhea - Pipeline by Protagonist Therapeutics Inc, H1 2020
Diarrhea - Pipeline by RaQualia Pharma Inc, H1 2020
Diarrhea - Pipeline by Rebiotix Inc, H1 2020
Diarrhea - Pipeline by RedHill Biopharma Ltd, H1 2020
Diarrhea - Pipeline by RxBio Inc, H1 2020
Diarrhea - Pipeline by Scandinavian Biopharma Holding AB, H1 2020
Diarrhea - Pipeline by Synthetic Biologics Inc, H1 2020
Diarrhea - Pipeline by Syntiron LLC, H1 2020
Diarrhea - Pipeline by VenatoRx Pharmaceuticals Inc, H1 2020
Diarrhea - Pipeline by Yisheng Biopharma Co Ltd, H1 2020
Diarrhea - Dormant Projects, H1 2020
Diarrhea - Dormant Projects, H1 2020 (Contd..1), H1 2020
Diarrhea - Dormant Projects, H1 2020 (Contd..2), H1 2020
Diarrhea - Discontinued Products, H1 2020

【掲載企業】

Akthelia Pharmaceuticals Ltd
Albireo Pharma Inc
Allergan Plc
Artugen Therapeutics Ltd
AzurRx BioPharma Inc
Boston Pharmaceuticals Inc
Chongqing Zhifei Biological Products Co Ltd
Codagenix Inc
Cosmo Pharmaceuticals NV
DiscoveryBiomed Inc
Glycosyn LLC
Immuron Ltd
Kaleido Biosciences Inc
Kuhnil Pharmaceutical Co Ltd
Miyarisan Pharmaceutical Company Ltd
MSD Wellcome Trust Hilleman Laboratories Pvt Ltd
MyBiotics Pharma Ltd
Napo Pharmaceuticals Inc
Nippon Shinyaku Co Ltd
Novartis AG
Orphomed Inc
Pharmascience Inc
Prokarium Ltd
Protagonist Therapeutics Inc
RaQualia Pharma Inc
Rebiotix Inc
RedHill Biopharma Ltd
RxBio Inc
Scandinavian Biopharma Holding AB
Synthetic Biologics Inc
Syntiron LLC
VenatoRx Pharmaceuticals Inc
Yisheng Biopharma Co Ltd

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[下痢治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆